News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

Tenax Therapeutics, Inc. (NASDAQ: TENX) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.

Tenax Therapeutics, Inc. (NASDAQ: TENX) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $16.00 price target on the stock.

Tenax Therapeutics, Inc. (NASDAQ: TENX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $16.00 price target on the stock.

Form SC 13G TENAX THERAPEUTICS, INC. Filed by: Lind Global Fund II LP

Form SC 13G/A TENAX THERAPEUTICS, INC. Filed by: JANUS HENDERSON GROUP PLC

Form SC 13G/A TENAX THERAPEUTICS, INC. Filed by: CVI Investments, Inc.

Form SC 13G/A TENAX THERAPEUTICS, INC. Filed by: Stonepine Capital Management, LLC

Form 10-Q TENAX THERAPEUTICS, INC. For: Sep 30

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}